CERENOME, INC.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-15.
0001193125-26-226978
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-14.
0001193125-26-352444
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 13 previous paragraphs and 11 current paragraphs.
8 unchanged; 0 reworded; 3 added; 5 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 1 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
The current filing states there were no material changes to risk factors.
This is the filer’s own statement, not a conclusion from the comparison. Read its qualifications and the report it references.
Current filing’s statement
There have been no material changes to the risk factors disclosed in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025.
Added paragraphs (3)
Removed paragraphs (5)
Previous report
The following table provides certain information with respect to the Company's purchases of its common stock for the three months ended March 31, 2026.
Previous report
On March 4, 2025, the Company entered into the March 2025 SPA with the March 2025 Private Placement Purchasers for the March 2025 Private Placement . On June 17, 2025, the Company and the Purchasers entered into the Letter Agreement with each of the Purchasers in an effort to, among other items, minimize the dilutive impact of the March 2025 Private Placement and provided for the return and cancellation of Private Placement Shares and Pre-Funded Warrants. The Private Placement Shares and Pre-Funded Warrants were repurchased by the Company pursuant to the Letter Agreement. Refer to Note 12 Stockholders’ Equityin Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on the Letter Agreement.
Previous report
On May 12, 2026, the Company filed a Certificate of Correction (the “Certificate of Correction”) to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) that was previously filed on April 1, 2026. The Certificate of Amendment erroneously stated the number of authorized shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) as 200,000,000 (two hundred million).
Previous report
As corrected by the Certificate of Correction, the total number of authorized shares of Common Stock is two billion (2,000,000,000).